Follow
BORA LIM
Title
Cited by
Cited by
Year
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ...
Annals of Oncology 32 (5), 661-672, 2021
6622021
Inflammatory breast cancer biology: the tumour microenvironment is key
B Lim, WA Woodward, X Wang, JM Reuben, NT Ueno
Nature Reviews Cancer 18 (8), 485-499, 2018
2952018
Androgen receptor function and androgen receptor–targeted therapies in breast cancer: a review
M Kono, T Fujii, B Lim, MS Karuturi, D Tripathy, NT Ueno
JAMA oncology 3 (9), 1266-1273, 2017
2142017
Advancing cancer research and medicine with single-cell genomics
B Lim, Y Lin, N Navin
Cancer cell 37 (4), 456-470, 2020
2082020
Breast tumours maintain a reservoir of subclonal diversity during expansion
DC Minussi, MD Nicholson, H Ye, A Davis, K Wang, T Baker, M Tarabichi, ...
Nature 592 (7853), 302-308, 2021
1492021
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
T Fujii, T Kogawa, W Dong, AA Sahin, S Moulder, JK Litton, D Tripathy, ...
Annals of Oncology 28 (10), 2420-2428, 2017
1462017
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
F Le Du, BL Eckhardt, B Lim, JK Litton, S Moulder, F Meric-Bernstam, ...
Oncotarget 6 (15), 12890, 2015
1412015
Discovery and clinical introduction of first-in-class imipridone ONC201
JE Allen, CLB Kline, VV Prabhu, J Wagner, J Ishizawa, N Madhukar, ...
Oncotarget 7 (45), 74380, 2016
1402016
Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis
P Li, M Lu, J Shi, Z Gong, L Hua, Q Li, B Lim, XHF Zhang, X Chen, S Li, ...
Nature immunology 21 (11), 1444-1455, 2020
1212020
Targeting TRAIL in the treatment of cancer: new developments
B Lim, JE Allen, VV Prabhu, MK Talekar, NK Finnberg, WS El-Deiry
Expert opinion on therapeutic targets 19 (9), 1171-1185, 2015
1132015
International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference
NT Ueno, JRE Fernandez, M Cristofanilli, B Overmoyer, D Rea, ...
Journal of Cancer 9 (8), 1437, 2018
1092018
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
E Miller, HJ Lee, A Lulla, L Hernandez, P Gokare, B Lim
F1000Research 3, 2014
1072014
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
WS El-Deiry, N Vijayvergia, J Xiu, A Scicchitano, B Lim, NS Yee, ...
Cancer biology & therapy 16 (12), 1726-1737, 2015
992015
Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system
TM Fouad, AMG Barrera, JM Reuben, A Lucci, WA Woodward, ...
The Lancet Oncology 18 (4), e228-e232, 2017
982017
Inflammatory breast cancer: what to know about this unique, aggressive breast cancer
A Menta, TM Fouad, A Lucci, H Le-Petross, MC Stauder, WA Woodward, ...
Surgical Clinics 98 (4), 787-800, 2018
952018
Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy
R Soundararajan, JJ Fradette, JM Konen, S Moulder, X Zhang, ...
Cancers 11 (5), 714, 2019
912019
Targeting apoptosis in cancer
P Singh, B Lim
Current oncology reports 24 (3), 273-284, 2022
882022
Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer
KW Evans, E Yuca, SS Scott, M Zhao, N Paez Arango, CX Cruz Pico, ...
Cancer research 81 (21), 5572-5581, 2021
822021
Current challenges of metastatic breast cancer
B Lim, GN Hortobagyi
Cancer and Metastasis Reviews 35, 495-514, 2016
792016
Novel therapeutic strategies in the treatment of triple-negative breast cancer
K Oualla, HM El-Zawahry, B Arun, JM Reuben, WA Woodward, ...
Therapeutic advances in medical oncology 9 (7), 493-511, 2017
712017
The system can't perform the operation now. Try again later.
Articles 1–20